Prelude Therapeutics Incorporated - Common Stock (PRLD)
Frequently Asked Questions About Prelude Therapeutics Incorporated - Common Stock (PRLD)
Has Prelude Therapeutics received any funding?
Yes, Prelude Therapeutics has secured funding through various rounds of investments, including its successful IPO. The company has attracted capital from institutional and private investors who support its vision and pipeline of targeted therapies.
How does Prelude Therapeutics contribute to the community?
Prelude Therapeutics is committed to contributing to the community through various initiatives, including partnerships with local organizations, sponsoring cancer research programs, and participating in awareness campaigns. The company aims to make a positive impact beyond its clinical goals.
How does Prelude Therapeutics identify drug candidates?
Prelude Therapeutics employs a proprietary drug discovery platform that integrates advanced computational biology, high-throughput screening, and extensive preclinical studies to identify and develop drug candidates. This innovative approach allows the company to pinpoint promising compounds that can effectively target the molecular drivers of cancer.
How has Prelude navigated challenges in the biotech industry?
Like many biotech firms, Prelude Therapeutics has faced challenges such as regulatory hurdles and market competition. However, by leveraging its strong scientific foundation and focusing on strategic collaborations, Prelude has successfully advanced its drug candidates while maintaining an emphasis on innovation and patient-centric solutions.
Is Prelude Therapeutics publicly traded?
Yes, Prelude Therapeutics is publicly traded on the NASDAQ stock exchange under the ticker symbol 'PRLD'. The company went public through an initial public offering (IPO) to raise capital for its research and development efforts.
What are Prelude's goals for the next few years?
In the coming years, Prelude Therapeutics aims to advance multiple drug candidates through clinical trials, expand its research pipeline, and explore opportunities for strategic partnerships. The company is committed to maximizing its impact on the oncology landscape and delivering new treatment options for patients.
What are some of the other drug candidates in Prelude's pipeline?
In addition to PRT543, Prelude Therapeutics has several other drug candidates in various stages of development. These include PRT811, a PRMT5 inhibitor, and PRT364, a novel therapeutic targeting certain hematologic malignancies. Each of these candidates is designed to address unmet medical needs in oncology.
What are the clinical trials Prelude Therapeutics is currently conducting?
Prelude Therapeutics is actively conducting several clinical trials to evaluate the safety and efficacy of its lead drug candidates, including Phase 1b and Phase 2 trials for PRT543. These trials aim to assess the therapeutic potential of their compounds in patients with specific types of cancers.
What collaborations does Prelude Therapeutics have?
Prelude Therapeutics has established several strategic collaborations with academic institutions and industry partners to enhance its research and development efforts. These collaborations focus on advancing cancer research, sharing knowledge, and optimizing drug discovery processes.
What does Prelude Therapeutics do?
Prelude Therapeutics Incorporated is a biopharmaceutical company focused on the discovery and development of novel therapeutics for patients with cancer. The company's innovative approach employs its proprietary drug discovery platform to develop targeted therapies that aim to address specific genetic and biological drivers of cancer.
What is Prelude's lead product candidate?
Prelude's lead product candidate is PRT543, a small-molecule inhibitor designed to target the protein PRMT5, which is implicated in various cancers. The company is advancing PRT543 through clinical trials to evaluate its safety and efficacy in treating different forms of cancer.
What is the company's long-term vision?
Prelude Therapeutics envisions becoming a leader in the field of precision oncology by developing revolutionary targeted therapies for cancer patients. The company aims to expand its pipeline, continue advancing promising drug candidates, and ultimately improve treatment outcomes for individuals affected by cancer.
What is the management team's experience?
The management team at Prelude Therapeutics brings a wealth of experience in the biopharmaceutical industry, with backgrounds in drug development, clinical research, and corporate strategy. Many team members have previously held leadership roles in successful biotech companies and have extensive knowledge of navigating the drug development landscape.
What is the mission of Prelude Therapeutics?
The mission of Prelude Therapeutics is to discover and develop innovative therapies for patients with cancer. The company aims to deliver medicines that provide meaningful benefits through targeted treatment, ultimately improving survival rates and quality of life for patients.
When was Prelude Therapeutics founded?
Prelude Therapeutics was founded in 2016. Since its inception, the company has made significant strides in its mission to provide transformative medicines for cancer patients, leveraging its expertise in molecular biology and drug development.
Where is Prelude Therapeutics located?
Prelude Therapeutics is headquartered in Durham, North Carolina. This location is part of the Research Triangle Park, which is known for its concentration of biotechnology and pharmaceutical companies and research institutions.
Who are Prelude Therapeutics' competitors?
Prelude Therapeutics operates within the competitive landscape of the biopharmaceutical industry, where other companies such as AstraZeneca, Gilead Sciences, and various biotechnology startups focus on cancer therapeutics. Prelude differentiates itself through its specialized research and targeted drug development strategies.
Who are the founders of Prelude Therapeutics?
Prelude Therapeutics was co-founded by a team of experienced professionals in the biotechnology and pharmaceutical industry, including executives with backgrounds in drug discovery and development. Their leadership has been instrumental in guiding the company toward its goals.
What is the current price of Prelude Therapeutics Incorporated - Common Stock?
The current price of Prelude Therapeutics Incorporated - Common Stock is 1.350
When was Prelude Therapeutics Incorporated - Common Stock last traded?
The last trade of Prelude Therapeutics Incorporated - Common Stock was at 4:00 pm EST on November 11th, 2025
What is the market capitalization of Prelude Therapeutics Incorporated - Common Stock?
The market capitalization of Prelude Therapeutics Incorporated - Common Stock is 73.99M
How many shares of Prelude Therapeutics Incorporated - Common Stock are outstanding?
Prelude Therapeutics Incorporated - Common Stock has 54.81M shares outstanding.